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Background:Whether the occurrence of refeeding syndrome (RFS), a metabolic condition characterized by electrolyte shifts after
initiation of nutritional therapy, has a negative impact on clinical outcomes remains ill-defined. We prospectively investigated a
subgroup of patients included in a multicentre, nutritional trial (EFFORT) for the occurrence of RFS.
Methods: In this secondary analysis of a randomized-controlled trial investigating the effects of nutritional support in
malnourished medical inpatients, we prospectively screened patients for RFS and classified them as “RFS confirmed” and “RFS
not confirmed” based on predefined criteria (i.e. electrolyte shifts, clinical symptoms, clinical context, and patient history). We
assessed associations of RFS and mortality within 180 days (primary endpoint) and other secondary endpoints using multivariable
regression analysis.
Results: Among 967 included patients, RFS was confirmed in 141 (14.6%) patients. Compared to patients with no evidence for
RFS, patients with confirmed RFS had significantly increased 180-daysmortality rates (42/141 (29.8%) vs 181/826 (21.9%), adjusted
odds ratio (OR) 1.53 (95% CI 1.02 to 2.29), P< .05). Patients with RFS also had an increased risk for ICU admission (6/141 (4.3%)
vs 13/826 (1.6%), adjusted OR 2.71 (95% CI 1.01 to 7.27), P< .05) and longer mean length of hospital stays (10.5±6.9 vs 9.0±6.6
days, adjusted difference 1.57 days (95% CI 0.38–2.75), P= .01).
Conclusion: A relevant proportion of medical inpatients with malnutrition develop features of RFS upon hospital admission, which
is associated with long-term mortality and other adverse clinical outcomes. Further studies are needed to develop preventive
strategies for RFS in this patient population.
Abbreviations: BMI = body mass index, CI = confidence interval, EFFORT = effect of early nutritional support on frailty, functional
outcomes and recovery of malnourished medical inpatients trial, EKNZ = The ethical committee of the Northwestern part of
Switzerland, HR = hazard ratio, ICU = intensive care unit, IQR = interquartile range (25th-75th percentiles), NRS = nutritional risk
screening, OR = odds ratio, RFS = refeeding syndrome, SD = standard deviation.
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Refeeding syndrome (RFS) is a metabolic condition characterized
by severe electrolyte and fluid shifts in response to the transition
from a catabolic to an anabolic state after start of nutritional
therapy in malnourished patients.[1–4] The clinical presentation
may vary from mild forms with few clinical signs and symptoms
to severe forms with possible lethal complications.[5] The
function of several organs can be affected by RFS leading to
cardiac arrhythmias, heart failure, and kidney failure among
other impairments.[6–10] There is currently insufficient knowledge
about predisposing factors, incidence rates, and treatment
options. It also remains largely unclear whether RFS is associated
with worse clinical courses and has thus prognostic implica-
tions.[11] A recent systematic literature review[12] revealed a lack
of large-scale, prospective studies systematically looking at the
occurrence of RFS, and high heterogeneity of definition criteria
used regarding electrolyte cut-offs and clinical criteria to classify
patients.[12]
Importantly, recent research has questioned whether RFS has
any prognostic implications regarding mortality risk. Death
attributable to RFS was found in only 4 out of 260,000 hospital
deaths in 1 large retrospective study from Australia looking at
patients over a 20 year time period.[13] Arguably, there was a high
risk for under-reporting in this investigation relying on coded
data from the hospital because no accepted gold standard for RFS
exists today and the diagnosis may often be missed in clinical
routine.[14] Also, a prospective cohort study including 243
patients found RFS to be a relatively rare consequence of
nutritional therapy and no causal relationship between RFS and
adverse outcome was reported.[1] In addition, a recent systematic
review found that only few studies reported data on the
association between RFS and clinical outcome.[12] Due to the
small number of patients and studies, the lack of statistical
adjustment for confounding factors and the high heterogeneity in
regard to patient population and setting, the systematic review[12]
was not able to draw any firm conclusion regarding the question
on whether RFS is indeed associated with adverse clinical
outcome.[12] Answering this question, however, is important as it
may help to justify screening and therapeutic measures in patients
at risk of RFS.
Herein, our aim was to systematically study the occurrence of
RFS in a large andwell characterized population of malnourished
patients included in a recent trial based on previously
published consensus criteria[4] and to investigate whether RFS
was indeed associated with adverse clinical outcomes within a
follow-up of 6 months.2. Methods
2.1. Study design and setting
This is a pre-planned secondary analysis of the prospective
EFFORT trial (Effect of early nutritional support on Frailty,
Functional Outcomes, and Recovery of malnourished medical
inpatients Trial). EFFORT was a pragmatic, investigator-
initiated, open-label, multicentre randomized controlled trial,
which recruited patients from April 2014 to February 2018 in 8
Swiss hospitals. The ethical committee of the Northwestern part
of Switzerland (EKNZ; 2014_001) approved the study protocol
and all patients or their authorized representatives provided
written informed consent. The trial was registered at Clinical-
Trials.gov (https://clinicaltrials.gov/ct2/show/NCT02517476).2The main aim of EFFORT was to assess the effects of early
nutritional therapy on patient outcomes in the medical inpatient
setting. The rationale for the trial, design details, and eligibility
features have been published previously[15] as have the main
results of the trial.[16]2.2. Patient population
EFFORT enrolled consecutive patients at nutritional risk (defined
by a Nutritional Risk Screening total score (NRS 2002) ≥3
points)[17,18] with an expected length of hospital stay ≥5 days if
they were willing to provide informed consent. Patients were
excluded if initially admitted to intensive care units or surgical
units, unable to ingest oral nutrition, already receiving nutritional
support on admission, with a terminal condition (i.e., end-of-life
situation), hospitalized because of anorexia nervosa, acute
pancreatitis, acute liver failure, cystic fibrosis or stem cell
transplantation, after gastric bypass surgery, or with contra-
indications for nutritional support, and patients previously
included in the trial. While EFFORT included a total of 2088
patients, this secondary analysis includes 967 medical inpatients
recruited in 2 of the 8 participating centers (Medical University
Department, Kantonsspital Aarau and University Hospital Bern),
which took part in this sub-study between February 2015 and
December 2017.2.3. Assessment of RFS and management of patients
Assessment of patients regarding RFS was done prospectively
according to a pre-defined checklist based on recent consensus
criteria for RFS.[4] In brief, included patients were screened daily
by a study dietician for possible RFS based on new occurrence or
worsening of laboratory parameters (hypophosphatemia, hypo-
kalemia, hypomagnesemia) or clinical parameters (peripheral
oedema). In case of possible RFS, a more detailed assessment of
patients was done by the study dietician and the treating
physician. Patients meeting either ≥2 minor criteria (phosphate
<0.81mmol/l, magnesium <0.74mmol/l, potassium <3.6mmol/
l, peripheral oedema) or ≥1 major criteria (phosphate <0.32
mmol/l, magnesium <0.5mmol/l, potassium <2.5mmol/l) un-
derwent further clinical examination focusing on clinical
symptoms such as peripheral oedema, tachycardia, and tachyp-
nea. Based on these parameters, the clinical context (i.e., other
explanations for oedema or electrolyte shifts) and the overall
patient history, a final classification regarding RFS was done and
patients were prospectively classified as “RFS confirmed” or
“RFS not confirmed”. This classification was primarily done by
the study physician, and in case of doubt a senior physician was
asked for a final judgment. Treatment of RFS in patients with
confirmed RFS was up to the treating physician team, without
interference of the study team, and included substitution of
electrolytes and B-complex vitamins as well as a gradually
increase of energy targets, as appropriate.2.4. Outcome measures
The primary endpoint of the EFFORT trial was defined as all-
cause long-term mortality within 180 days. To verify survival
status as well as other clinical outcomes, we performed telephone
interviews at 30 and 180 days in all patients. If patients or their
relatives could not be reached, we verified outcome data with the
patient’s primary care provider. Secondary endpoints were short-
Friedli et al. Medicine (2020) 99:1 www.md-journal.comterm (i.e., within 30 days) mortality, admission to intensive care
unit, non-elective hospital readmission after discharge, major
complications (including adjudicated nosocomial infection,
respiratory failure, a major cardiovascular event or pulmonary
embolism, acute renal failure, gastro-intestinal events, or a
decline in functional status of 10% or more from admission to
day 30) and length of hospital stay of the index hospital stay. A
more detailed description of endpoints has previously been
published in the study protocol.[15]
2.5. Statistical analysis
Statistical analyses were performed using STATA 12.1 (STATA
Corp, College Station, TX, USA). We used descriptive statistics
including mean with standard deviation to describe the study
population as appropriate. Categorical variables are expressed as
percentages (numbers) and continuous variables as medians
(interquartile ranges (IQRs)).
We did 2 main analyses, first focusing on all patients and
comparing patients with confirmed RFS to patients with no RFS.
Second, we focused on the subgroup of patients with possible
RFS during screening and compared patients with confirmed RFS
to patients with not confirmed RFS. For primary and secondary
endpoints we calculated odds ratios (ORs) and 95% confidence
intervals (CIs) using univariable and multivariable logistic
regression analysis.[19] We adjusted the analysis for important
prognostic factors such as patient age, gender, and BMI. All tests
were carried out at 5% significance levels.
3. Results
3.1. Patient population
This analysis includes 967 patients that were screened for RFS
during their index hospital stay in 2 study centers participating in
this sub-study. A total of 353 (36.5%) of these patients had
electrolyte changes or clinical signs possibly related to RFS and
were reassessed in more detail for RFS. Among these, 141
patients were classified as “RFS confirmed” and 212 patients
were classified as “RFS not confirmed”. Thus, as shown in
Figure 1, RFS was confirmed in 141 (14.6%) patients whereas
826 (85.4%) patients had no RFS (212 with abnormalities
during screening, but no RFS confirmation; and 614 with no
abnormalities at screening).
In a first step, we compared baseline results from patients with
RFS to all patients with no RFS including patients with no
abnormalities during screening (Table 1). Results were similar
and showed differences in regards to initial randomization, some
comorbidities and more frequent use of oral nutrition supple-
ments in patients with confirmed RFS.
Second, we focused on patients with abnormalities during
screening and compared patients with confirmed RFS (n=141) to
patients where RFS was not confirmed (n=212). Table 2 shows
baseline characteristics of these patients stratified according to
RFS classification. Compared to patients without confirmed RFS,
patients with confirmed RFS had a higher rate of appetite loss at
baseline (87.9% vs 78.8%; OR 1.97, 95% CI 1.07–3.60,
P= .028). Patients in the intervention group of the EFFORT trial
also had a higher likelihood of RFS (47.2% vs 61%, adjusted OR
1.75 (95%CI 1.14–2.7), P= .011). Comorbidities such as
hypertension and cancer were significantly different in both
groups. Nutritional support among both groups was similar, but
patients with confirmed RFS received more often oral nutrition3supplements (26.4% vs 40.3%, adjusted OR 1.88 (95%CI 1.18–
2.98), P= .008).3.2. Laboratory findings
Next, we focused on laboratory results that were ordered in the
subgroup of patients with abnormalities during the screening
process (n=353). Table 3 shows detailed results of laboratory
results stratified by RFS. At baseline, levels of phosphate (mmol/l)
(0.74 vs 0.93; difference 0.09, 95% CI 0.04–0.22, P< .001),
magnesium (mmol/l) (0.67 vs 0.73; difference 0.10, 95% CI
0.02–0.42, P= .002), potassium (mmol/l) (3.46 vs 3.79; differ-
ence 0.25, 95% CI 0.15–0.41, P< .001) and albumin (g/L) (25.5
vs 27.2; difference 0.94, 95% CI 0.90–0.99, P= .011) were
significantly lower in patients with confirmed RFS versus patients
with no confirmed RFS, respectively. In addition, laboratory
results of electrolytes in RFS patients were also lower when
measured during follow-up.We found no significant difference in
clinical symptoms between groups except for tachycardia being
more frequent in patients with confirmed RFS at follow-up
(12.2% vs 3.6%; OR 3.75, 95% CI 1.43–9.85, P= .007).3.3. Association of RFS and adverse outcome
Regarding the primary endpoint, a total of 42/141 (29.8%)
patients with confirmed RFS died within the 180 days of follow
up (Table 4). This was a significantly higher number compared to
all patients with no RFS (181/826 (21.9%), adjusted OR 1.53
(95% CI 1.02 to 2.29), P= .038) and also when compared to
patients who presented abnormalities during screening but no
confirmation of RFS (37/212 (17.5%), adjusted OR 1.97, 95%
CI 1.18 to 3.29, P= .01). Figure 2 shows Kaplan–Meier curves
for time to death within 6 months comparing patients with
confirmed RFS to patients without RFS and patients with no
confirmed RFS.
Regarding secondary endpoints, compared to patients with no
RFS, patients with confirmed RFS showed an increased risk for
ICU admission (4.3% vs 1.6%, adjusted OR 2.71 (95%CI 1.01–
7.27), P.048) and an increase in length of hospital stay (10.5 vs
9.0 days, adjusted difference 1.57 days (95%CI 0.38–2.75),
P= .01). Comparing patients with confirmed to patients with not
confirmed RFS there was a doubling in 30-day readmission rate
(9.9% vs 4.2%, adjusted OR 2.42 (95% CI 1.01–5.81),
P= .047). There were no significant differences in other
secondary endpoints (Table 4).4. Discussion
Key results of this secondary analysis of a previous interventional
trial are two-fold. First, we found that a relevant proportion of
medical inpatients at risk of malnutrition develop RFS, based on
the evaluation of laboratory and clinical parameters, affecting
about 1 of 7 patients. Second, within this large and well-
characterized population of medical inpatients at risk for
malnutrition with systematic short- and long-term assessment,
we found an association between the occurrence of RFS and long-
term mortality within a follow-up period of 180 days. There was
also an increase in unplanned hospital readmissions, as well as
ICU admissions and days in the hospital when compared to the
overall population of patients with no RFS. Thus these data
provide empiric evidence that RFS is a potentially harmful
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Figure 1. Flow chart. Patient Assessment of Refeeding Syndrome after inclusion in the EFFORT trial in 2 of the 8 participating centres (Medical University
Department, Kantonsspital Aarau and University Hospital Bern, which took part in this sub-study). RFS=Refeeding Syndrome.
Table 1







(odds ratio or coefficient and 95%CI, P value)
Socio-demographics
Age - yr, median (IQR) 74 (64.0, 82.0) 73.0 (63.0, 80.0) ∗1.00 (0.89 to 1.14), P= .959
Male sex, n (%) 440 (53.3%) 84 (59.6%) 1.29 (0.90 to 1.86), P= .166
Nutritional history
☆Body mass Index (BMI) - kg/m2, mean (SD) 25.3 (5.5) 24.6 (4.9) 0.97 (0.94 to 1.01), P= .119
BMI WHO, n (%)
18.5–24.9 416 (50.6%) 75 (53.6%) Reference
<18.5 49 (6.0%) 13 (9.3%) 1.47 (0.76 to 2.84), P= .251
≥25 357 (43.4%) 52 (37.1%) 0.81 (0.55 to 1.18), P= .272
☆☆Nutritional risk score (NRS 2002), n (%)
3 points 249 (30.1%) 28 (19.9%) Reference
4 points 313 (37.9%) 60 (42.6%) 1.70 (1.06 to 2.75), P= .029
5 points 201 (24.3%) 46 (32.6%) 2.04 (1.23 to 3.37), P= .006
6 points 63 (7.6%) 7 (5.0%) 0.99 (0.41 to 2.37), P= .979
Weight loss, n (%)
5% in 3 month 485 (58.7%) 67 (47.5%) Reference
(continued )










(odds ratio or coefficient and 95%CI, P value)
>5% in 3 month 99 (12.0%) 22 (15.6%) 1.61 (0.95 to 2.73), P= .078
>5% in 2 month 92 (11.1%) 20 (14.2%) 1.57 (0.91 to 2.72), P= .104
>5% in 1 month 150 (18.2%) 32 (22.7%) 1.54 (0.98 to 2.44), P= .064
Loss of appetite, n (%)
No 124 (15.0%) 17 (12.1%) Reference
Yes 702 (85.0%) 124 (87.9%) 1.29 (0.75 to 2.21), P= .359
Food intake of normal requirement preceding week, n (%)
> 75% 111 (13.4%) 12 (8.5%) Reference
50–75% 240 (29.1%) 33 (23.4%) 1.27 (0.63 to 2.56), P= .499
25–50% 316 (38.3%) 65 (46.1%) 1.90 (0.99 to 3.65), P= .053
<25% 159 (19.2%) 31 (22.0%) 1.80 (0.89 to 3.66), P= .103
Severity of illness, n (%)
very mild 10 (1.2%) 2 (1.4%) Reference
mild 463 (56.1%) 74 (52.5%) 0.80 (0.17 to 3.72), P= .775
moderate/ severe 353 (42.7%) 65 (46.1%) 0.92 (0.2 to 4.3), P= .916
Study group, n (%)
Control group 423 (51.2%) 55 (39.0%) Reference
Intervention group 403 (48.8%) 86 (61.0%) 1.64 (1.14 to 2.36), P= .008
Main diagnosis at hospital presentation, n (%)
Cardiovascular disease 85 (10.3%) 8 (5.7%) 0.52 (0.25 to 1.11), P= .091
Infectious disease 274 (33.2%) 43 (30.5%) 0.88 (0.60 to 1.30), P= .532
Metabolic disorder 27 (3.3%) 5 (3.5%) 1.09 (0.41 to 2.87), P= .865
Gastrointestinal disease 27 (3.3%) 15 (10.6%) 1.77 (0.97 to 3.24), P= .064
Renal disease 33 (4.0%) 6 (4.3%) 1.07 (0.44 to 2.60), P= .885
Cancer 143 (17.3%) 39 (27.7%) 1.83 (1.21 to 2.75), P= .004
Neurological disease 37 (4.5%) 2 (1.4%) 0.31 (0.07 to 1.29), P= .106
Lung disease 48 (5.8%) 3 (2.1%) 0.35 (0.11 to 1.15), P= .083
Frailty 72 (8.7%) 11 (7.8%) 0.89 (0.46 to 1.72), P= .72
Other 28 (3.4%) 7 (5.0%) 1.49 (0.64 to 3.48), P= .358
Comorbidities, n (%)
Coronary heart disease 186 (22.5%) 33 (23.4%) 1.05 (0.69 to 1.60), P= .816
Congestive heart failure 146 (17.7%) 19 (13.5%) 0.73 (0.43 to 1.21), P= .222
Hypertension 429 (51.9%) 87 (61.7%) 1.49 (1.03 to 2.15), P= .032
Renal failure 288 (34.9%) 44 (31.2%) 0.85 (0.58 to 1.24), P= .398
Diabetes mellitus 182 (22.0%) 34 (24.1%) 1.12 (0.74 to 1.71), P= .584
COPD 112 (13.6%) 17 (12.1%) 0.87 (0.51 to 1.51), P= .628
Cancer 254 (30.8%) 65 (46.1%) 1.93 (1.34 to 2.77), P< .001
Nutritional support during the trial
Intensified hospital kitchen only, n (%) 198 (26.8%) 43 (32.1%) 1.29 (0.87 to 1.92), P= .211
Additional use of oral nutritional supplements, n (%) 211 (28.3%) 54 (40.3%) 1.71 (1.17 to 2.50), P= .006
Enteral tube feeding, n (%) 4 (0.5%) 3 (2.2%) 4.18 (0.92 to 18.87), P= .063
Parenteral nutrition, n (%) 5 (0.7%) 1 (0.7%) 1.10 (0.13 to 9.52), P= .928
Nutritional intake, mean (SD)
Mean intake until day 5
Energy intake (total calories per day) 1416.9 (518.4) 1333.2 (546.0) ∗∗0.97 (0.94 to 1.00), P= .089
Protein intake (gram per day) 54.8 (22.0) 52.0 (23.5) ∗∗∗0.94 (0.87 to 1.03), P= .182
Mean intake until day 7
Energy intake (total calories per day) 1435.2 (508.7) 1382.1 (517.2) ∗∗0.98 (0.94 to 1.02), P= .264
Protein intake (gram per day) 55.7 (21.4) 54.0 (22.5) ∗∗∗0.96 (0.89 to 1.05), P= .408
Mean intake until day 10
Energy intake (total calories per day) 1452.0 (508.5) 1403.9 (506.5) ∗∗0.98 (0.95 to 1.02), P= .309
Protein intake (gram per day) 56.4 (21.3) 55.3 (22.1) ∗∗∗0.98 (0.9 to 1.06), P= .567
Weight changes during the trial - kg, mean (SD)
Baseline weight 72.7 (17.1) 71.3 (16.7) ∗∗∗∗0.95 (0.85 to 1.07), P= .438
weight day 3 72.6 (17.5) 72.3 (19.4) ∗∗∗∗0.99 (0.86 to 1.14), P= .893
weight day 6 72.5 (16.9) 71.3 (16.4) ∗∗∗∗0.96 (0.85 to 1.07), P= .451
Data are presented as median (IQR), mean (SD) or % (no.). P values are statistically significant at P< .05.
Data for univariable analyses are given as odds ratios (95% CI) and P value. All odds ratios were calculated with logistic regression for binary data and linear regression for continuous data.
☆ The body-mass index is the weight in kilograms divided by the square of the height in meters.
☆☆ Scores on nutritional risk screening range from 0 to 7, with a score of 3 or more identifying patients at nutritional risk and higher scores indicating increased risk.
∗ OR in 10-years increments
∗∗ OR in 100 calories increments.
∗∗∗ OR in 10 g increments.
∗∗∗∗ OR in 10 kg increments.
RFS=Refeeding Syndrome.
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(odds ratio or coefficient
and 95%CI, P value)
Socio-demographics
Age - yr, median (IQR) 75.0 (62.0, 82.0) 73.0 (63.0, 80.0)
∗
1.05 (0.91 to 1.21), P= .524
Male sex, n (%) 110 (51.9%) 84 (59.6%) 1.37 (0.89 to 2.10), P= .156
Nutritional history
☆Body mass Index (BMI) - kg/m2, mean (SD) 25.2 (5.2) 24.6 (4.9) 0.97 (0.93 to 1.02), P= .226
BMI WHO, n (%)
18.5–24.9 114 (53.8%) 75 (53.6%) Reference
<18.5 12 (5.7%) 13 (9.3%) 1.65 (0.71 to 3.80), P= .243
≥25 86 (40.6%) 52 (37.1%) 0.92 (0.59 to 1.44), P= .714
☆☆Nutritional risk score (NRS 2002), n (%)
3 points 59 (27.8%) 28 (19.9%) Reference
4 points 73 (34.4%) 60 (42.6%) 1.73 (0.98 to 3.05), P= .057
5 points 57 (26.9%) 46 (32.6%) 1.70 (0.94 to 3.08), P= .08
6 points 23 (10.8%) 7 (5.0%) 0.64 (0.25 to 1.67), P= .363
Weight loss, n (%)
5% in 3 month 125 (59.0%) 67 (47.5%) Reference
>5% in 3 month 17 (8.0%) 22 (15.6%) 2.41 (1.20 to 4.86), P= .013
>5% in 2 month 25 (11.8%) 20 (14.2%) 1.49 (0.77 to 2.88), P= .233
>5% in 1 month 45 (21.2%) 32 (22.7%) 1.33 (0.77 to 2.28), P= .306
Loss of appetite, n (%)
No 45 (21.2%) 17 (12.1%) Reference
Yes 167 (78.8%) 124 (87.9%) 1.97 (1.07 to 3.60), P= .028
Food intake of normal requirement preceding week, n (%)
>75% 40 (18.9%) 12 (8.5%) Reference
50–75% 51 (24.1%) 33 (23.4%) 2.16 (0.99 to 4.70), P= .053
25–50% 75 (35.4%) 65 (46.1%) 2.89 (1.40 to 5.97), P= .004
<25% 46 (21.7%) 31 (22.0%) 2.25 (1.02 to 4.95), P= .045
Severity of illness, n (%)
very mild 3 (1.4%) 2 (1.4%) Reference
mild 102 (48.1%) 74 (52.5%) 1.09 (0.18 to 6.68), P= .927
moderate / severe 107 (50.5%) 65 (46.1%) 0.91 (0.15 to 5.60), P= .92
Randomisation, n (%)
Control group 112 (52.8%) 55 (39.0%) Reference
Intervention group 100 (47.2%) 86 (61.0%) 1.75 (1.14 to 2.7), P= .011
Main diagnosis at hospital presentation, n (%)
Cardiovascular disease 12 (5.7%) 8 (5.7%) 1.00 (0.40 to 2.52), P= .996
Infectious disease 85 (40.1%) 43 (30.5%) 0.66 (0.42 to 1.03), P= .067
Metabolic disorder 11 (5.2%) 5 (3.5%) 0.67 (0.23 to 1.98), P= .47
Gastrointestinal disease 11 (5.2%) 15 (10.6%) 2.18 (0.97 to 4.89), P= .06
Renal disease 8 (3.8%) 6 (4.3%) 1.13 (0.38 to 3.34), P= .82
Cancer 29 (13.7%) 39 (27.7%) 2.41 (1.41 to 4.13), P= .001
Neurological disease 11 (5.2%) 2 (1.4%) 0.26 (0.06 to 1.20), P= .085
Lung disease 9 (4.2%) 3 (2.1%) 0.49 (0.13 to 1.84), P= .292
Frailty 23 (10.8%) 11 (7.8%) 0.70 (0.33 to 1.48), P= .344
Other 33 (15.6%) 7 (5.0%) 2.16 (0.67 to 6.95), P= .196
Comorbidities, n (%)
Coronary heart disease 41 (19.3%) 33 (23.4%) 1.27 (0.76 to 2.14), P= .359
Congestive heart failure 32 (15.1%) 19 (13.5%) 0.88 (0.47 to 1.62), P= .672
Hypertension 108 (50.9%) 87 (61.7%) 1.55 (1.01 to 2.39), P= .047
Renal failure 73 (34.4%) 44 (31.2%) 0.86 (0.55 to 1.36), P= .528
Diabetes mellitus 54 (25.5%) 34 (24.1%) 0.93 (0.57 to 1.52), P= .773
COPD 33 (15.6%) 17 (12.1%) 0.74 (0.40 to 1.39), P= .356
Cancer 56 (26.4%) 65 (46.1%) 2.38 (1.52 to 3.74), P< .001
Nutritional support during the trial
Intensified hospital kitchen only, n (%) 58 (28.2%) 43 (32.1%) 1.21 (0.75 to 1.94), P= .438
Additional use of oral nutritional supplements, n (%) 55 (26.4%) 54 (40.3%) 1.88 (1.18 to 2.98), P= .008
Enteral tube feeding, n (%) 1 (0.5%) 3 (2.2%) 4.66 (0.48 to 45.27), P= .185
Parenteral nutrition, n (%) 2 (1.0%) 1 (0.7%) 0.77 (0.07 to 8.54), P= .829
Nutritional intake, mean (SD)
Mean intake until day 5
Energy intake (total calories per day) 1441.2 (541.7) 1333.2 (546.0) ∗∗0.96 (0.93 to 1.00), P= .075
Protein intake (gram per day) 54.2 (21.5) 52.0 (23.5) ∗∗∗0.96 (0.87 to 1.05), P= .368
Mean intake until day 7
Energy intake (total calories per day) 1460.0 (524.7) 1382.1 (517.2) ∗∗0.97 (0.93 to 1.01), P= .177
Protein intake (gram per day) 55.0 (20.7) 54.0 (22.5) ∗∗∗0.98 (0.88 to 1.08), P= .672
Mean intake until day 10
Energy intake (total calories per day) 1476.0 (525.0) 1403.9 (506.5) ∗∗0.97 (0.93 to 1.02), P= .207
Protein intake (gram per day) 55.6 (20.6) 55.3 (22.1) ∗∗∗0.99 (0.90 to 1.10), P= .892
Weight changes during the trial - kg, mean (SD)
Baseline weight 72.4 (16.7) 71.3 (16.7) ∗∗∗∗0.96 (0.83 to 1.11), P= .573
weight day 3 73.0 (17.1) 72.3 (19.4) ∗∗∗∗0.98 (0.83 to 1.15), P= .788
weight day 6 72.2 (16.4) 71.3 (16.4) ∗∗∗∗0.97 (0.84 to 1.11), P= .642
Data are presented as median (IQR), mean (SD) or % (no.). P values are statistically significant at P< .05.
Data for univariable analyses are given as odds ratios (95% CI) and P value. All odds ratios were calculated with logistic regression for binary data and linear regression for continuous data.
☆ The body-mass index is the weight in kilograms divided by the square of the height in meters.
☆☆ Scores on nutritional risk screening range from 0 to 7, with a score of 3 or more identifying patients at nutritional risk and higher scores indicating increased.
∗ OR in 10-years increments.
∗∗ OR in 100 calories increments.
∗∗∗ OR in 10 g increments.
∗∗∗∗ OR in 10 kg increments.
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Time course, mean (SD)
Occurrence of RFS- days 1.8 (1.9) 2.4 (3.6) 1.10 (0.96 to 1.25), P= .158
Laboratory findings
Phosphate at baseline mmol/l, mean (SD) 0.93 (0.32) 0.74 (0.29) 0.09 (0.04 to 0.22), P< .001
≥0.81 mmol/l, n (%) 119 (58.0%) 31 (22.0%) Reference
0.32–0.81 mmol/l, n (%) 84 (41.0%) 108 (76.6%) 4.94 (3.03 to 8.03), P< .001
<0.32 mmol/l, n (%) 2 (1.0%) 2 (1.4%) 3.84 (0.52 to 28.35), P= .187
Phosphate follow-up mmol/l, mean (SD) 0.97 (0.25) 0.82 (0.27) 0.08 (0.03 to 0.24), P< .001
≥0.81 mmol/l, n (%) 138 (76.7%) 52 (46.0%) Reference
0.32–0.81 mmol/l, n (%) 41 (22.8%) 60 (53.1%) 2.73 (1.62 to 4.58), P< .001
<0.32 mmol/l, n (%) 1 (0.6%) 1 (0.9%) 2.65 (0.16 to 43.21), P= .493
Delta (D) phosphate mmol/l, mean (SD) 0.04 (0.28) 0.09 (0.32) 1.86 (0.81 to 4.27), P= .142
Magnesium at baseline mmol/l, mean (SD) 0.73 (0.16) 0.67 (0.14) 0.10 (0.02 to 0.42), P= .002
≥0.74 mmol/l, n (%) 101 (49.0%) 34 (24.1%) Reference
0.5–0.74 mmol/l, n (%) 85 (41.3%) 92 (65.2%) 3.22 (1.97 to 5.24), P< .001
<0.5 mmol/l, n (%) 20 (9.7%) 15 (10.6%) 2.23 (1.03 to 4.83), P= .043
Magnesium follow-up mmol/l, mean (SD) 0.75 (0.15) 0.67 (0.15) 0.03 (0.00 to 0.16), P< .001
≥0.74 mmol/l, n (%) 105 (58.0%) 35 (32.4%) Reference
0.5–0.74 mmol/l, n (%) 66 (36.5%) 60 (55.6%) 2.73 (1.62 to 4.58), P< .001
<0.5 mmol/l, n (%) 10 (5.5%) 13 (12.0%) 3.90 (1.57 to 9.68), P= .003
Delta (D) magnesium mmol/l, mean (SD) 0.02 (0.14) 0.003 (0.153) 0.31 (0.05 to 1.85), P= .198
Potassium at baseline mmol/l, mean (SD) 3.79 (0.56) 3.46 (0.43) 0.25 (0.15 to 0.41), P< .001
≥3.6 mmol/l, n (%) 135 (64.0%) 56 (39.7%) Reference
2.5–3.6 mmol/l, n (%) 76 (36.0%) 83 (58.9%) 2.63 (1.70 to 4.09), P< .001
<2.5 mmol/l, n (%) 0 (0.0%) 2 (1.4%) NA
Potassium follow-up mmol/l,mean (SD) 3.91 (0.47) 3.67 (0.56) 0.38 (0.23 to 0.61), P< .001
≥3.6 mmol/l, n (%) 152 (79.2%) 66 (53.7%) Reference
2.5–3.6 mmol/l, n (%) 40 (20.8%) 55 (44.7%) 3.17 (1.92 to 5.22), P< .001
<2.5 mmol/l, n (%) 0 (0.0%) 2 (1.6%) NA
Delta (D) potassium mmol/l, mean (SD) 0.11 (0.56) 0.23 (0.62) 1.40 (0.95 to 2.08), P= .092
Albumin at baseline g/l, mean (SD) 27.22 (5.82) 25.53 (4.92) 0.94 (0.90 to 0.99), P= .011
Albumin follow-up g/l, mean (SD) 25.92 (5.26) 24.52 (5.68) 0.95 (0.91 to 1), P= .069
Delta (D) albumin mmol/l, mean (SD) 0.11 (2.99) 0.59 (4.18) 0.97 (0.89 to 1.04), P= .383
Clinical findings
Peripheral oedema at baseline, n (%) 28 (13.2%) 22 (15.6%) 1.21 (0.66 to 2.22), P= .528
Peripheral oedema follow-up, n (%) 21 (10.8%) 17 (17.9%) 1.81 (0.9 to 3.61), P= .095
Tachycardia at baseline, n (%) 18 (8.5%) 17 (12.1%) 1.48 (0.73 to 2.98), P= .274
Tachycardia follow-up, n (%) 7 (3.6%) 12 (12.2%) 3.75 (1.43 to 9.85), P= .007
Tachypnoea at baseline, n (%) 9 (4.2%) 8 (5.7%) 1.36 (0.51 to 3.60), P= .541
Tachypnoea follow-up, n (%) 1 (0.5%) 2 (2.0%) 4.02 (0.36 to 44.9), P= .258
Electrolyte supplementation
Phosphate supplement, n (%) 22 (10.4%) 58 (41.1%) 6.04 (3.47 to 10.51), P< .001
Amount of phosphat supplement mmol/l, mean (SD) 42.77 (41.74) 62.56 (26.34) 1.02 (1.00 to 1.04), P= .015
Magnesium supplement, n (%) 49 (23.1%) 51 (36.2%) 1.89 (1.18 to 3.01), P= .008
Amount of magnesium supplement mmol/l, mean (SD) 12.66 (7.12) 13.90 (7.38) 1.02 (0.97 to 1.08), P= .393
Potassium supplement, n (%) 60 (28.3%) 69 (48.9%) 2.43 (1.56 to 3.79), P< .001
Amount of potassium supplement mmol/l, mean (SD) 52.50 (23.77) 53.91 (25.10) 1.00 (0.99 to 1.02), P= .742
Calcium supplement, n (%) 17 (8.0%) 26 (18.4%) 2.59 (1.35 to 4.98), P= .004
Amount of calcium supplement mmol/l, mean (SD) 18.71 (15.25) 13.63 (4.61) 0.93 (0.82 to 1.04), P= .214
Data are presented as mean (SD) or % (no.). P values are statistically significant at P< .05.
Data for univariable analyses are given as odds ratios (95% CI) and P value. All odds ratios were calculated with logistic regression for binary data and linear regression for continuous data.
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of care treatments in many hospitals to lower the burden of
morbidity associated with disease-related malnutrition.[11,18,20]
NICE guidelines[21] have proposed several risk factors for RFS
including low BMI, unwanted weight loss, starvation, alcohol
abuse, and low levels of some electrolytes on admission. Our data
largely confirms this and other previous reports about risk factors
for RFS showing that loss of appetite, reduced dietary intake, use7of nutritional supplements, and a history of cancer are strongly
associated with RFS occurrence.[22,23] Yet, NRS[17] total score
and low BMI was not associated with RFS in our analysis which
may be explained by the fact that the original trial only included
patients at risk of malnutrition, i.e. with a NRS of at least 3
points. In addition, we found low levels of phosphate, potassium,
magnesium, and albumin at admission to be associated with an
increased risk of RFS after start of nutritional support. These risk
Table 4













Mortality within 180 days, n (%) 42 (29.8%) 181 (21.9%) 1.51 (1.02 to 2.25), P= .041 1.53 (1.02 to 2.29), P= .038
Secondary endpoints
Mortality within 30 days, n (%) 11 (7.8%) 76 (9.2%) 0.84 (0.43 to 1.61), P= .592 0.82 (0.42 to 1.59), P= .554
Admission to the ICU within 30 days, n (%) 6 (4.3%) 13 (1.6%) 2.78 (1.04 to 7.44), P= .042 2.71 (1.01 to 7.27), P= .048
Hospital readmission within 30 days, n (%) 14 (9.9%) 62 (7.5%) 1.36 (0.74 to 2.5), P= .325 1.34 (0.73 to 2.48), P= .343
Major complications within 30 days, n (%) 8 (5.7%) 59 (7.1%) 0.78 (0.37 to 1.67), P= .526 0.80 (0.37 to 1.71), P= .558
Length of hospital stay - days, mean (SD) 10.5 (6.9) 9.0 (6.6) 1.50 (0.32 to 2.69), P= .013 1.57 (0.38 to 2.75), P= .01












Mortality within 180 days, n (%) 42 (29.8%) 37 (17.5%) 2.01 (1.21 to 3.33), P= .007 1.97 (1.18 to 3.29), P= .01
Secondary endpoints
Mortality within 30 days, n (%) 11 (7.8%) 15 (7.1%) 1.11 (0.49 to 2.5), P= .798 1.08 (0.48 to 2.45), P= .855
Admission to the ICU within 30 days, n (%) 6 (4.3%) 2 (0.9%) 4.67 (0.93 to 23.46), P= .062 4.62 (0.92 to 23.37), P= .064
Hospital readmission within 30 days, n (%) 14 (9.9%) 9 (4.2%) 2.49 (1.05 to 5.91), P= .039 2.42 (1.01 to 5.81), P= .047
Major complications within 30 days, n (%) 8 (5.7%) 14 (6.6%) 0.85 (0.35 to 2.08), P= .724 0.87 (0.35 to 2.16), P= .769
Length of hospital stay - days, mean (SD) 10.5 (6.9) 9.8 (6.7 0.70 (0.75 to 2.15), P= .34 0.66 (0.79 to 2.11), P= .373
Data are presented as mean (SD) or % (no.). P values are statistically significant at P< .05.
Data for univariable and multivariable analyses are given as odds ratios (95% CI) and P value. All odds ratios were calculated with logistic regression. Multivariate regression analysis was adjusted for predefined
prognostic factors (adjusting for age, gender and BMI). ICU denotes intensive care unit.
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P<0.05
 Mortality for patients with RFS compared to all patients with no RFS
Mortality for patients with RFS compared to patients with RFS not confirmed
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B
Figure 2. Time to mortality analysis over 180 days of follow-up. Plots showing
the association between the primary endpoint all-cause long-term mortality
within 180 days and patients with RFS compared to those with no RFS or not
confirmed RFS. RFS=Refeeding Syndrome.
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RFS during hospital stay. Still, whether or not preventive
measures are effective in reducing the associated risks of RFS
remain unclear and cannot be answered with our study.
Importantly, our findings also confirm previous findings
regarding timing of the occurrence of RFS. Similar to the results
of a previous meta-analysis, we also found that in most patients
RFS occurs within the first 72hours after the start of nutritional
therapy.[12] Thus, close monitoring of risk factors and clinical
features of RFS during this initial vulnerable time period seems
appropriate to detect patients with RFS.
The pathophysiology of RFS is still incompletely understood,
but there seem to be several metabolic factors causing this
condition.[24–26] During starvation and other catabolic con-
ditions, secretion of glucagon increases while insulin secretion
decreases leading to an activated gluconeogenesis and proteoly-
sis. Additionally, electrolyte supplies and intracellular vitamin,
such as thiamine, are depleted.[6,27] After the start of nutritional
intake, glucose concentration rises followed by an increase in
insulin and decrease of glucagon secretion. Insulin stimulates
glycogen, fat, and protein synthesis, which requires minerals and
cofactors, such as phosphate, magnesium, and thiamine. Insulin
also leads to an uptake of glucose and potassium into the cell
through the sodium-potassium ATPase symporter. Phosphate
and magnesium are absorbed and water follows by osmosis.[27]
The result of this transcellular shift is a redistribution of
electrolytes with extracellular volume expansion resulting from
increased sodium and water retention.[12] The volume overload
can lead to peripheral oedema and heart failure, while the
transcellular shift of electrolytes is a risk for arrhythmias or
spasms.[6,10] Changes in electrolytes thus may precede clinical
symptoms and screening of electrolytes derangements in at-risk
Friedli et al. Medicine (2020) 99:1 www.md-journal.compatients is therefore reasonable. A recent expert consensus on the
topic proposed to classify patients as imminent RFS if severe
laboratory changes occur, and manifest RFS if clinical symptoms
are also present.[4] Our data support these considerations
showing a strong association between baseline laboratory
parameters and later occurrence of RFS. Still, whether systematic
treatment of patients with electrolytes and vitamins reduces RFS
and its associated risks remains uncertain.
In our initial EFFORT paper, we reported low rates of RFS and
did not find a higher risk for RFS according to randomization,
while in the current analysis RFS was diagnosed more frequently
and nutritional intervention was associated with the occurrence
of RFS. Importantly, we used a different definition for RFS in the
initial trial and we did not perform routine RFS screening in all
patients, but only patients with clinically apparent RFS reached
the safety endpoint. In this sub-study, we systematically screened
and assessed all patients for possible RFS based on a consensus
definition. Thus, underreporting is likely in our EFFORT trial
and also in other previous studies relying on routine data and
reporting low number of RFS and lack of association with
outcomes.[1,12–14] Interestingly, mortality was significantly lower
in intervention group patient compared to controls in EFFORT
although the intervention seems to be associated with risk for
RFS. Possibly, the use of micronutrients as part of the
intervention had a preventive effect in the trial. This hypothesis,
however, needs further confirmation in future research.
The strength of our research is the prospective screening and
assessment of a large population of patients, with predefined
diagnostic criteria and long-term follow-up. However, we are
aware of some limitations. We relied our RFS definition on a
previous consensus statement because no gold standard currently
exists. Laboratory parameters were not routinely available on a
daily basis in all patients but were ordered systematically on
admission and on day 2 of hospital stay, and were based on the
clinical situation. We only screened patients in 2 out of 8
participating hospitals due to limited resources. Nevertheless, the
cohort with a total of 967 screened patients is among the largest
studies investigating RFS. Further, based on our trial, we only
focused on medical inpatient at nutritional risk and thus
generalizability to other populations and settings is uncertain.
5. Conclusion
The prognostic importance of RFS has been questioned mainly
because clinical data showing strong associations of RFSwithworse
clinical outcomes have been largely lacking. Herein, our data
provide strong evidence that patients classified as RFS based on a
recent consensus definition have a doubling inmortality risk, and an
increase also in other adverse clinical outcomes. Our data illustrate
that a relevant proportion of medical patients with malnutrition
developRFS upon hospital admission, which puts them at increased
risk for adverse clinical outcomes. Future studies should investigate
preventivemeasures to improveoutcomes in this patient population.
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